Home › Therapeutic areas › Neurology › Major Depressive Disorder
Major Depressive Disorder (12 companies)
Companies with an active program in Major Depressive Disorder.
| Ticker | Company | Therapeutic areas | Programs | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| ATAI | Atai Beckley | Neurology | 3 | Phase 2 | $2.73B | 5 |
| AXSM | Axsome Therapeutics | Neurology Rare | 2 | Approved | $6.96B | 15 |
| CMPS | COMPASS Pathways | Neurology | 1 | NDA Submitted | $1.22B | 3 |
| CTNM | Contineum Therapeutics | NeurologyRespiratory Rare | 1 | Phase 2 | $374M | 4 |
| DFTX | Definium Therapeutics | Neurology | 1 | Phase 3 | $4.47B | 4 |
| GHRS | GH Research | NeurologyWomen's Health | 2 | Phase 2 | $1.28B | 4 |
| HELP | Helus Pharma | Neurology | 1 | Phase 3 | $655M | 3 |
| LBRX | LB Pharmaceuticals | Neurology | 1 | Phase 3 | $1.36B | 3 |
| NRXP | NRX Pharmaceuticals | Neurology Rare | 3 | Approved | $103M | 7 |
| RVPH | Reviva Pharmaceuticals | CardiovascularDermatology+2 Rare | 2 | Phase 3 | $4.8M | 10 |
| VNDA | Vanda Pharmaceuticals | CardiovascularDermatology+6 Rare | 1 | Approved | $231M | 27 |
| XENE | Xenon Pharmaceuticals | Neurology Rare | 1 | NDA Submitted | $3.79B | 9 |
No companies match.